x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

45:02

357: The upheaval of CDC's vaccine panel, and drug...

The Readout Loud ·

2025/06/12

First, we chat about how pharma companies still don’t have much clarity on Trump’s most-favored nation drug pricing policy, biotech’s next big takeout target, and more. Then we bring on Kathryn Edwards, a vaccine expert and a former member of the CDC advisory panel, to parse through the turmoil.

en

33:05

356: An AI experiment at the FDA & Novo trailing in...

The Readout Loud ·

2025/06/05

The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition. This week, we’ll chat about Sanofi’s $9 billion offer for Blueprint Medicines. But first, our cohost Elaine Chen has a new story published this week that examines the reasons behind Novo Nordisk’s fall and what it’s doing to catch up.

en

36:55

355: Moderna’s vaccine hit, the MAHA report, and an...

The Readout Loud ·

2025/05/29

The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Then, STAT’s infectious disease reporter Helen Branswell joins us to discuss RFK Jr.’s unprecedented move to strike Covid shot recommendations, and the cancellation of a $600 million contract with Moderna to develop, test and license vaccines for subtypes of flu. We also welcome chronic disease reporter Isa Cueto to discuss the key takeaways from a

en

41:30

354: Uncertainty in CRISPR world and the start of...

The Readout Loud ·

2025/05/22

We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT reporter Jason Mast to talk about the latest research and sentiment at the annual American Society of Cell and Gene Therapy meeting.

en

25:47

353: Trump's drug-pricing plan and a potential...

The Readout Loud ·

2025/05/15

We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Elizabeth Holmes' husband. We also bring on STAT's D.C. correspondent Daniel Payne to talk about President Trump's "most-favored nation" drug pricing policy and health secretary Robert F. Kennedy Jr.'s recent congressional hearing.

en

26:28

352: A firebrand takes oversight of vaccines, gene...

The Readout Loud ·

2025/05/08

Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad's tenure could be.

en

35:19

351: It's gonna be May (in biotech)

The Readout Loud ·

2025/05/01

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem. The first 100 days of the Trump administration have had a profound impact on federal health agencies, medical research, health policy and the biotech and pharmaceuticals industries. To help us make sense of all the cuts and policy shifts, we talk with STAT editors Gideon Gil and Zach Tracer for their perspective overseeing STAT’s

en

31:40

350: Pharma tariffs, and a 'sunshine day' for biotech...

The Readout Loud ·

2025/04/24

How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship's latest startup centered around "preemptive medicine"? And who among the co-hosts is the best singer?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb's schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal,

en

40:55

349: BIO's John Crowley on RFK Jr. and tariffs, plus...

The Readout Loud ·

2025/04/10

John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.'s comments on Novavax's Covid-19 vaccine, and how the trade group is communicating with the Trump administration. Then we discuss the latest news on the stock market and a congressional advisory group's recommendation that $15 billion be invested in U.S. biotechnology to ward off encroaching competition from China.

en

31:10

348: Cuts, ousters and drama at the FDA

The Readout Loud ·

2025/04/03

STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign at a time when newly sworn-in FDA Commissioner Makary is still figuring out how to get around the agency’s White Oak campus in suburban Maryland. Then: AstraZeneca presented positive mid-stage results this week on a PCSK9 pill that dramatically lowered cholesterol levels on top of traditional statins. R&D executive Sharon Barr joins to talk about why

en

31:25

347: More HHS upheaval, 23andMe's bankruptcy, and AI...

The Readout Loud ·

2025/03/27

Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.

en

42:34

346: Zealand's obesity strategy and Immunovant's...

The Readout Loud ·

2025/03/20

We chat about positive data from Immunovant's autoimmune drug candidate, a patient death linked to Sarepta's gene therapy, and dispatches from our STAT Breakthrough Summit East in New York. We also bring on Zealand Pharma CEO Adam Steensberg to talk about his company’s amylin-targeting obesity treatment, the partnership deal it recently signed with Roche, and his thoughts on the industry's intense focus on weight loss.

en

31:00

345: The sudden withdrawal of a CDC nominee and what...

The Readout Loud ·

2025/03/13

We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the CDC just hours before Weldon's confirmation hearing. It's also the five-year anniversary of the Covid-19 pandemic. We chat with Princeton political scientist Frances Lee about a new book she co-authored that offers an unflinching assessment of the U.S. policy responses to the pandemic and raises some provocative questions about what went wrong.

en

25:51

344: Trump's FDA commissioner nominee takes the hot seat

The Readout Loud ·

2025/03/06

Will Marty Makary be confirmed as the next commissioner of the Food and Drug Administration? Will he bring back employees laid off by DOGE? And what did he get wrong during his confirmation hearing? We discuss all that and more during this week's special episode.

en

32:01

343: Turbulence at the FDA, Bluebird Bio's sale and...

The Readout Loud ·

2025/02/27

It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.

en

41:00

342: FDA cuts, zombie biotechs, and too much weight...

The Readout Loud ·

2025/02/20

Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.

en

26:39

341: NIH funding cuts, a U.S. brain drain, and bold...

The Readout Loud ·

2025/02/13

We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedical innovation. We also chat with health tech reporter Brittany Trang about the claims that two drug developers, Absci and Generate:Biomedicines, have made about the capabilities of their artificial intelligence technologies, and why some experts are skeptical.

en

34:45

340: Crisis in CRISPR world, RFK Jr.'s promises, and...

The Readout Loud ·

2025/02/06

We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

en

34:29

339: RFK Jr.'s confirmation hearings, MASH drugs, and...

The Readout Loud ·

2025/01/30

Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.). But first, we chat about Akero Therapeutics and the results reported this week from a study of its experimental drug that showed, for the first time, reversal of cirrhosis in patients with severe MASH. We critique that Hims & Hers commercial. And lastly, we talk about a new fund from biotech

en

33:09

338: Chinese biotechs, a WHO departure, and post-JPM...

The Readout Loud ·

2025/01/23

We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporter Helen Branswell joins us to explain the implications of Trump's decision to pull the U.S. out of the WHO.

en

381 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...